1. Indications and Usage
\nNon-Pancreatic Neuroendocrine Tumors (npNETs):
\nIndicated for the treatment of adult patients with unresectable locally advanced or metastatic, progressive, non-functional, well-differentiated (G1\/G2) non-pancreatic neuroendocrine tumors.
\nPancreatic Neuroendocrine Tumors (pNETs):
\nIndicated for the treatment of adult patients with unresectable locally advanced or metastatic, progressive, non-functional, well-differentiated (G1\/G2) pancreatic neuroendocrine tumors.
\n2. Dosage and Administration
\nRoute of Administration:
\nOral Use ONLY.
\nRecommended Dosage:
\nMonotherapy: 300 mg (six 50 mg capsules) administered orally once daily.
\nCombination Therapy: 250 mg (five 50 mg capsules) administered orally once daily.
\nDuration: Continue daily for 4 weeks as one cycle until disease progression or unacceptable toxicity.
\nAdministration Instructions:
\nSwallow capsules whole with water; do not crush or chew.
\nCan be taken on an empty stomach or with a low-calorie meal (approx. 500 kcal, 20% fat).
\nMissed Dose:
\nIf a dose is missed, do not take it. Resume at the regularly scheduled time for the next dose. If vomiting occurs after administration, do not take an extra dose.
\n3. Mechanism of Action
\nMulti-kinase Inhibition:
\nSurufatinib is a small molecule tyrosine kinase inhibitor that targets three key receptors:
\n1. VEGFR1-3 (Vascular Endothelial Growth Factor Receptors): Inhibits tumor angiogenesis.
\n2. FGFR1-4 (Fibroblast Growth Factor Receptors): Inhibits tumor growth and survival.
\n3. CSF1R (Colony Stimulating Factor 1 Receptor): Modulates the tumor microenvironment by inhibiting M2 macrophage polarization.
\n4. Safety and Warnings
\nProteinuria:
\nMonitor urine protein regularly. In case of severe proteinuria (\u2265 3g\/24h), treatment should be interrupted or dose-adjusted.
\nHypertension:
\nMonitor blood pressure regularly. Initiate antihypertensive therapy as needed.
\nBleeding Risk:
\nMonitor for signs of bleeding. Contraindicated in patients with severe active bleeding.
\nHepatic Impairment:
\nMonitor liver function tests regularly. Contraindicated in patients with severe hepatic impairment.
\n5. Adverse Reactions
\nMost Common:
\nProteinuria, hypertension, hyperbilirubinemia, diarrhea, hypoalbuminemia, hypertriglyceridemia, elevated ALT\/AST, fatigue, abdominal pain, and peripheral edema.
\n6. Drug Interactions
\nCYP3A4 Modulators:
\nSurufatinib is metabolized by CYP3A4. Avoid concomitant use with strong CYP3A4 inhibitors or inducers.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Surufatinib (available in 50 mg and 100 mg strengths).
\nStorage:
\nStore in a tightly closed container in a dry place at a temperature not exceeding 30\u00b0C.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u82cf\u6cf0\u8fbe\u00ae(Sulanda\u00ae)
\nGeneric Name: Surufatinib
\nStrength: 50mg per capsule
\nManufacturer: Hutchison MediPharma (Suzhou) Co., Ltd.
\nMarketing Authorization Holder: Hutchison MediPharma (Shanghai) Co., Ltd.
\nApproval Date in China: December 30, 2020
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 H20200017
\nStorage: Sealed, store at room temperature (10\u2103 ~ 30\u2103), keep away from children and direct sunlight.<\/p>\n
Price&Cost:Contact Us now for the best price of Surufatinib(Sulanda\uff09<\/p>\n","protected":false},"featured_media":3423,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[96],"product_cat":[26,73],"product_tag":[],"class_list":["post-3422","product","type-product","status-publish","has-post-thumbnail","product_brand-hutchison","product_cat-capsules","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n